HOPE SPV receives US$819,000 second tranche of funding
Filed with ASX · · 2 pages · English
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- September 2023 Quarterly Activities Report
- Zelira closes $3.25M funding as part of HOPE SPV fundraise
- June 2023 Quarterly Activities Report
- Zeliras diabetic nerve pain drug outperforms Lyrica
- Trading Halt
Later from Zelira Therapeutics
- December 2023 Quarterly Activities Report
- Appendix 4D & FY24 Interim Financial Report
- Zelira receives $919,000 R&D Tax Incentive Scheme Refund
- March 2024 Quarterly Activities Report
- HOPE SPV receives US$681,000 third tranche of funding
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics